Eagle Asset Management Inc. reduced its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,661,511 shares of the biopharmaceutical company’s stock after selling 36,991 shares during the quarter. Eagle Asset Management Inc. owned about 1.60% of Amicus Therapeutics worth $38,558,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Strs Ohio bought a new stake in Amicus Therapeutics during the third quarter worth approximately $102,000. Birchview Capital LP bought a new stake in Amicus Therapeutics during the third quarter worth approximately $151,000. Sage Capital Advisors llc bought a new stake in Amicus Therapeutics during the third quarter worth approximately $154,000. Engineers Gate Manager LP bought a new stake in Amicus Therapeutics during the third quarter worth approximately $155,000. Finally, Neuberger Berman Group LLC bought a new stake in Amicus Therapeutics during the third quarter worth approximately $196,000.
Several brokerages have weighed in on FOLD. BidaskClub cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. ValuEngine raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Leerink Swann boosted their price objective on Amicus Therapeutics from $20.00 to $24.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Cowen reissued a “buy” rating and set a $22.00 price objective on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. Finally, Zacks Investment Research raised Amicus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, January 17th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $19.06.
In other news, insider Jay Barth sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $16.80, for a total transaction of $336,000.00. Following the transaction, the insider now owns 105,409 shares of the company’s stock, valued at $1,770,871.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Bradley L. Campbell sold 32,500 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $15.92, for a total value of $517,400.00. Following the transaction, the chief operating officer now directly owns 186,600 shares in the company, valued at approximately $2,970,672. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 250,390 shares of company stock worth $3,620,581. Insiders own 3.40% of the company’s stock.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $15.17 on Friday. Amicus Therapeutics, Inc. has a 52 week low of $5.87 and a 52 week high of $17.40. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32.
TRADEMARK VIOLATION NOTICE: “Eagle Asset Management Inc. Has $38.56 Million Holdings in Amicus Therapeutics, Inc. (FOLD)” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/02/18/eagle-asset-management-inc-has-38-56-million-holdings-in-amicus-therapeutics-inc-fold.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.